{"entity":{"id":"michael-hallek","kind":"person","name":"Michael Hallek","aka":[],"tldr":"Leads the German CLL Study Group, whose trials (CLL8, CLL14, CLL13) set global standards for CLL treatment.","summary":"Michael Hallek is Director of Department I of Internal Medicine at University Hospital Cologne (CIO) and Head of the German CLL Study Group. His specialisms are chronic lymphocytic leukaemia, chemoimmunotherapy and targeted therapy trials, with a focus on BCL-2 and CD20. He led CLL8, which established the FCR regimen, CLL14, the New England Journal of Medicine trial of venetoclax and obinutuzumab in patients with CLL and coexisting conditions, and CLL13/GAIA. These trials moved CLL from chemotherapy to fixed-duration targeted therapy and set global standards. His publications are listed on PubMed.","asOf":"2026-09-08","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hallek%20M%5BAuthor%5D%20CLL"}],"tags":[],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":["bcl2","cd20"],"drugs":["venetoclax","obinutuzumab"],"companies":[],"institutions":["uniklinik-koeln"],"pathways":[],"terms":[],"trials":["cll14","cll13-gaia"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Department I of Internal Medicine, University Hospital Cologne; Head, German CLL Study Group","institutionId":"uniklinik-koeln","specialisms":["Chronic lymphocytic leukaemia","Chemoimmunotherapy","Targeted therapy trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hallek%20M%5BAuthor%5D%20CLL"}],"papers":[{"title":"Venetoclax and obinutuzumab in patients with CLL and coexisting conditions (CLL14)","journal":"NEJM","year":2019,"doi":"10.1056/NEJMoa1815281"}],"orcid":"0000-0002-7425-4455"},"route":"/people/michael-hallek/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"target":[{"id":"bcl2","kind":"target","name":"BCL-2","route":"/targets/bcl2/"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/"}],"drug":[{"id":"obinutuzumab","kind":"drug","name":"Obinutuzumab","route":"/drugs/obinutuzumab/"},{"id":"venetoclax","kind":"drug","name":"Venetoclax","route":"/drugs/venetoclax/"}],"institution":[{"id":"eha","kind":"institution","name":"European Hematology Association","route":"/institutions/eha/"},{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","route":"/institutions/uniklinik-koeln/"}],"trial":[{"id":"cll13-gaia","kind":"trial","name":"CLL13 / GAIA","route":"/trials/cll13-gaia/"},{"id":"cll14","kind":"trial","name":"CLL14","route":"/trials/cll14/"}],"paper":[{"id":"paper-cll14-venetoclax-obinutuzumab-nejm-2019","kind":"paper","name":"CLL14: one year of venetoclax plus obinutuzumab instead of chemo-immunotherapy in older, less fit CLL patients","route":"/key-papers/paper-cll14-venetoclax-obinutuzumab-nejm-2019/"}],"company":[{"id":"ghsg","kind":"company","name":"German Hodgkin Study Group","route":"/companies/ghsg/"}]}}